Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

1245 - Primary Neuroendocrine Tumor of the Maxilla: A Case Report


24 Nov 2018


Poster display - Cocktail


Tumour Site

Neuroendocrine Tumours


Crizel Denise Uy


C.D.V. Uy1, C.C.M. Esplana2, G. Fernando3

Author affiliations

  • 1 Department Of Internal Medicine, Philippine General Hospital, 1000 - Manila/PH
  • 2 Department Of Internal Medicine, Philippine General Hospital, 1701 - Manila/PH
  • 3 Medical Oncology, Philippine General Hospital, 1000 - Manila/PH


Abstract 1245

Case Summary

Background: Neuroendocrine tumors are a rare and heterogenous group of malignancies that arise from the neural crest cells with neuroendocrine differentiation. They account for only 0.5% of all malignancies with an incidence of 5-6 new cases per 100,000 inhabitants. While they most commonly arise from the gastro-intestinal tract and respiratory system, NETs likewise infrequently arise from the head and neck.
Aims: To present a rare case of a maxillary mass revealing to be a neuroendocrine tumor by histopathology. Methods/design: Case report.
Results: A case of a 64 year old male with a 5 month history of a slowly enlarging mass on the medial aspect of the left cheek bone. This was accompanied by facial erythema and numbness of the affected area. Due to the progressive enlargement of the mass, there was eventual extension to the orbital cavity resulting to compromised vision. As the metastatic work up was unremarkable, the patient underwent a subtotal maxillectomy with orbital exenteration. Histopathology revealed a malignant round cell tumor, 3.3cm in widest diameter, involving the posterior maxilla, lateral nasal mucosa, the orbital floor, lateral pterygoid and ethmoid mucosae, and the temporalis muscle. Immunohistochemistry studies reveal strong and diffusely positive for synaptophysin, chromogranin, and vimentin, while negative for CK and LCA, compatible with a neuroendocrine carcinoma. The patient underwent 6 cycles of adjuvant chemotherapy with cisplatin and etoposide. Evaluation scans were clear for residual or recurrent tumor, and the patient remains to be asymptomatic almost one year post treatment.
Summary/Conclusion: Neuroendocrine tumors rarely involve the head and neck but are usually aggressive with high rates of recurrence. Best outcomes are achieved using a multimodality approach using surgery, radiation, and a platinum-based chemotherapy. The importance for close surveillance should likewise be implemented due to frequent recurrence and metastases

Editorial acknowledgement

Clinical trial identification

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.